LifeVantage (NASDAQ:LFVN) issued an update on its FY 2020 earnings guidance on Wednesday morning. The company provided EPS guidance of $0.62-0.71 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.50. The company issued revenue guidance of $235-245 million, compared to the consensus revenue estimate of $226.94 million.
LifeVantage stock traded up $0.15 during mid-day trading on Wednesday, reaching $11.12. The company’s stock had a trading volume of 60,734 shares, compared to its average volume of 125,180. LifeVantage has a 12-month low of $9.30 and a 12-month high of $17.08. The firm has a market cap of $154.30 million, a P/E ratio of 21.80 and a beta of 0.66. The stock has a fifty day moving average of $11.67.
Separately, ValuEngine lowered shares of LifeVantage from a buy rating to a hold rating in a research report on Thursday, August 1st.
LifeVantage Corporation engages in the identification, research, development, and distribution of nutraceutical dietary supplements and skin care products. The company offers Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skin care product; Axio, a line of energy drink mixes; Omega+, a fish oil dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and Vitamin D3; and PhysIQ, a weight management system, as well as Petandim for Dogs, a companion pet supplement formulated to treat oxidative stress in dogs.
Read More: Elliott Wave Theory
Receive News & Ratings for LifeVantage Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifeVantage and related companies with MarketBeat.com's FREE daily email newsletter.